News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,736 Results
Type
Article (13945)
Company Profile (304)
Press Release (247487)
Section
Business (79362)
Career Advice (153)
Deals (13193)
Drug Delivery (34)
Drug Development (50328)
Employer Resources (31)
FDA (5682)
Job Trends (5116)
News (144143)
Policy (10018)
Tag
Academia (902)
Alliances (21525)
Alzheimer's disease (756)
Approvals (5661)
Artificial intelligence (68)
Bankruptcy (97)
Best Places to Work (4522)
Biotechnology (249)
Breast cancer (109)
Cancer (888)
Cardiovascular disease (71)
Career advice (133)
CAR-T (73)
Cell therapy (217)
Clinical research (40137)
Collaboration (308)
Compensation (128)
COVID-19 (1006)
C-suite (78)
Cystic fibrosis (66)
Data (983)
Diabetes (85)
Diagnostics (1207)
Drug discovery (56)
Earnings (29005)
Events (47196)
Executive appointments (247)
FDA (6047)
Funding (306)
Gene editing (63)
Gene therapy (163)
GLP-1 (310)
Government (1065)
Healthcare (6543)
Infectious disease (1043)
Inflammatory bowel disease (98)
IPO (7197)
Job creations (859)
Job search strategy (128)
Layoffs (188)
Legal (1375)
Lung cancer (130)
Lymphoma (62)
Manufacturing (86)
Medical device (2562)
Medtech (2563)
Mergers & acquisitions (6131)
Metabolic disorders (257)
Neuroscience (999)
NextGen Class of 2024 (2005)
Non-profit (847)
Northern California (1093)
Obesity (140)
Opinion (91)
Parkinson's disease (75)
Patents (61)
People (25107)
Phase I (14150)
Phase II (18664)
Phase III (11818)
Pipeline (367)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (201)
Real estate (1411)
Regulatory (8281)
Research institute (931)
Southern California (976)
Startups (1964)
United States (8657)
Vaccines (164)
Weight loss (83)
Date
Last 7 days (363)
Last 30 days (1373)
Last 365 days (20529)
2024 (20442)
2023 (22414)
2022 (26826)
2021 (27806)
2020 (23359)
2019 (16226)
2018 (11739)
2017 (13745)
2016 (11839)
2015 (14350)
2014 (10392)
2013 (7484)
2012 (7533)
2011 (7619)
2010 (7428)
Location
Africa (146)
Asia (16923)
Australia (2856)
California (2476)
Canada (809)
China (203)
Colorado (91)
Connecticut (103)
Europe (36446)
Florida (271)
Georgia (71)
Illinois (153)
Indiana (61)
Kansas (55)
Maryland (330)
Massachusetts (1955)
Minnesota (101)
New Jersey (630)
New York (682)
North Carolina (419)
Northern California (1093)
Ohio (82)
Pennsylvania (474)
South America (207)
Southern California (976)
Texas (278)
Washington State (247)
261,736 Results for "treadwell therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Treadwell Announces the Formation and Members of Scientific Advisory Board
Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet needs in cancer, announced the formation of a Scientific Advisory Board comprised of prominent oncology leaders and drug developers.
February 13, 2024
·
7 min read
Treadwell Therapeutics Announces a Presentation at the 2023 ASH Annual Meeting and Advisory Board Meeting
Treadwell Therapeutics today announced a presentation for the Company’s lead program, CFI-400945, a first-in-class inhibitor of Polo-like Kinase 4 (PLK4) being advanced in relapsed/refractory AML, at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held from December 9-12, 2023.
December 15, 2023
·
3 min read
Treadwell Announces Strategic Pipeline Prioritization and Leadership Transitions
Treadwell Therapeutics today announced that it is realigning its pipeline, workforce and management structure to support its highest value program and extend its cash runway to prioritize the execution of key near term value drivers and clinical milestones.
December 6, 2023
·
4 min read
Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation from U.S. FDA for the Treatment of Acute Myeloid Leukemia
Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet needs in cancer, today announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ocifisertib (CFI-400945), a first-in-class, investigational PLK4 inhibitor for the treatment of acute myeloid leukemia (AML).
February 20, 2024
·
2 min read
Business
Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer
Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.
February 3, 2023
·
2 min read
Business
Treadwell Therapeutics Announces the Appointment of J.D. Mowery, as Chief Operating Officer
Treadwell Therapeutics announced today the appointment of J.D. Mowery as Chief Operating Officer (COO).
April 19, 2022
·
2 min read
Pharm Country
Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer
Treadwell Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CFI-402257, a best in class inhibitor of Threonine Tyrosine Kinase (TTK, also known as Mps1), for the treatment of adult patients with ER+/HER2- advanced breast cancer after disease progression on prior CDK4/6 inhibitors and endocrine therapy, both as a monotherapy and in combination with fulvestrant.
January 10, 2023
·
2 min read
Pharm Country
Treadwell Therapeutics Announces A Presentation at the 2022 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor
Treadwell Therapeutics today announced that data presented on the ongoing CFI-402257-CL-001 clinical study of the Company’s CFI-402257 program in advanced solid tumors, continued to show a tolerable safety profile and demonstrated clinical benefit both as a monotherapy as well in combination with fulvestrant.
December 9, 2022
·
2 min read
Pharm Country
Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor
Treadwell Therapeutics today announced a presentation for the Company’s CFI-400945 program, a first in class inhibitor of Polo-like Kinase 4 (PLK4) a critical regulator of centriole duplication, at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held from December 10-13, 2022.
December 13, 2022
·
2 min read
Pharm Country
Treadwell Therapeutics Announces Presentations at the 2022 San Antonio Breast Cancer Symposium Featuring a Clinical Trial Update on the CFI-402257 and CFI-400945 programs
Treadwell Therapeutics today announced that four abstracts highlighting CFI-402257 and CFI-400945, the Company’s potent and selective inhibitors of TTK and PLK4, respectively, have been accepted for presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS) being held from December 6-10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
November 21, 2022
·
2 min read
1 of 26,174
Next